P. Patel

发表

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Quantification and prognostic significance of interferon-γ secreting SARS-CoV-2 responsive T cells in hospitalized patients with acute COVID-19

M. Barer, J. W. Kim, C. A. Martin, 2021, Journal of Infection.

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.

William F. Fadel, S. E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

William F. Fadel, S. E. Reese, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Waning of SARS-CoV-2 antibodies targeting the Spike protein in individuals post second dose of ChAdOx1 and BNT162b2 COVID-19 vaccines and risk of breakthrough infections: analysis of the Virus Watch community cohort.

A. Yavlinsky, A. Hayward, I. Braithwaite, 2021, medRxiv.

Serologic testing of U.S. blood donations to identify SARS-CoV-2-reactive antibodies: December 2019-January 2020

Kimberly D. Moss, C. Reed, A. Tamin, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Serologic Testing of US Blood Donations to Identify Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive Antibodies: December 2019–January 2020

Kimberly D. Moss, C. Reed, A. Tamin, 2020, Clinical Infectious Diseases.

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

William F. Fadel, C. Mcevoy, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines

N. Tolia, M. Murphy, M. Holbrook, 2023, Cell Reports.

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

William F. Fadel, Sarah E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, BMJ.

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

S. E. Reese, C. Mcevoy, S. Schrag, 2021, American Journal of Transplantation.

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, Pediatrics.

Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.

S. E. Reese, C. Mcevoy, P. Embí, 2022, The Journal of infectious diseases.

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, JAMA network open.

Empiric Addition of Quinolones to First-Line Tuberculosis Treatment Is Associated With Increased Odds of XDR-TB

Amita Gupta, Z. Udwadia, Samridhi Sharma, 2022, Frontiers in Tropical Diseases.

Estimated SARS-CoV-2 Seroprevalence Among Persons Aged <18 Years — Mississippi, May–September 2020

Manish M Patel, B. Flannery, T. Kittle, 2021, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 Vaccines at Preventing Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompromised Adults: An Observational Study of Real-World Data Across 10 US States from August-December 2021

S. E. Reese, C. Mcevoy, P. Embí, 2022, medRxiv.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

R. Link-Gelles, P. Embí, K. Natarajan, 2023, Lancet regional health. Americas.

Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network.

C. Mcevoy, P. Embí, B. Flannery, 2023, Journal of Infectious Diseases.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023.

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, American Journal of Transplantation.

Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19–Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions — VISION Network, September 2022–April 2023

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, MMWR. Morbidity and mortality weekly report.

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, medRxiv.